KR960705797A - 5-아릴이소옥사졸-4-일-치환된 2-아미노카르복실산 화합물(5-arylisoxa-zol-4-yl-substituted 2-amino carboxylic acid compounds) - Google Patents

5-아릴이소옥사졸-4-일-치환된 2-아미노카르복실산 화합물(5-arylisoxa-zol-4-yl-substituted 2-amino carboxylic acid compounds)

Info

Publication number
KR960705797A
KR960705797A KR1019960702307A KR19960702307A KR960705797A KR 960705797 A KR960705797 A KR 960705797A KR 1019960702307 A KR1019960702307 A KR 1019960702307A KR 19960702307 A KR19960702307 A KR 19960702307A KR 960705797 A KR960705797 A KR 960705797A
Authority
KR
South Korea
Prior art keywords
group
substituted
alkyl
compound
phenyl
Prior art date
Application number
KR1019960702307A
Other languages
English (en)
Inventor
시빌레 몰트첸 렌쯔
팔크 에리크
페테르 뵈게쇠 클라우스
크로그스가아르트-라르센 포블
Original Assignee
존 메이달 피터센
하. 룬트베크 악티에셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 존 메이달 피터센, 하. 룬트베크 악티에셀스카브 filed Critical 존 메이달 피터센
Publication of KR960705797A publication Critical patent/KR960705797A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

5-아릴이소옥사졸-4-일 또는 5-아릴이소티아졸-4-일로 치환되고 일반식(I)을 갖는 2-아미노카르복실산의 화합물:
상기 식에서, A는 결합 또는 스페이서기이며; B는 -CH(NR′R″)-COOH기 (상기 식에서 R′ 및 R″는 독립적으로 수소 또는 C1-6알킬임)이거나 일반식(Ⅱ)의 기이며
(상기 식에서, R2, R3및 R4는 치환기이거나, R3및 R4또는 R4및 R2는 연결되어 고리를 형성함); E는 0, S, COO, (CH2)n-COO, O-(CH2)n-COO 또는 S-(CH2)n-COO (상기식에서 n=1~6), 5-테트라졸일, 5-테트라졸일-C1-6알킬, 3-히드록시이소옥사졸일 또는 3-히드록시이소옥사졸일-C1-6알킬이며; D는 0 또는 S이며; R1은 임의적으로 치환된 아릴 또는 헤테로아릴기이다.
본 발명의 화합물은 뇌허혈, Huntington 질병, 간질병, Parkinson 질병, Alzheimer 질병, 정신분열증, 동통, 우울증 및 불안의 치료에 유용한 흥분성 아미노산 리셉터 리간드이다.

Description

5-아릴이소옥사졸-4-일-치환된 2-아미노카르복실산 화합물(5-ARYLISOXAZOL-4-YL-SUBSTITUTED 2-AMINO CARBOXYLIC ACID COMPOUNDS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 일반식 I를 갖는 (5-아릴이소옥사졸-4-일)- 또는 (5-아릴이소옥사졸-4-일)-치환된2-아미노카르복실산 화합물 또는 약학적으로 허용가능한 그것의 염:
    상기 식에서 A는 결합 또는 C1-6알킬렌, C2-6알킨일렌 또는 C2-6알켄일렌 및 시클로알킬렌으로부터 선택된 스페이서기이며; B는 R′가 R″가 독립적으로 수소 또는 C1-6알킬인 -CH(NR′R″)-COOH기이거나 일반식 Ⅱ의 기이며
    (상기 식에서 R2, R3및 R4는 a) 수소, C1-6알킬, C2-6알켄일, C2-6알킨일, 시클로알크 (엔)일, 시클로알크(엔)일-C1-6알크(엔/인)일, 페닐-C1-6알킬, 티에닐-C1-6-알킬, 및 b) 한개 이상의 탄소원자가 N, O 및/또는 S로 치환된 C1-6알킬, C2-6알켄일 및 C2-6알킨일로 구성된 군으로부터 독립적으로 선택되거나; R3및 R4는 연결되어 C2-6알킬렌, C2-6알켄일렌 또는 C2-6알킨일렌기를 형성하거나; R4및 R2는 연결되어 임의적으로 히드록시 또는 메틸로 모노- 또는 디-치환된 C1-C3알킬렌, C2-C3알켄일렌 또는 C2-C3알킨일렌기 또는 CH2-0-CH2를 형성한다); E는 0, S, COO, n이 1~6의 정수인 (CH2)n-COO, O-(CH2)n-COO 또는 S-(CH2)n-COO 이거나 5-테트라졸일기, 5-테트라졸일-C1-6알킬기, 3-히드록시-이소옥사졸일 또는 3-히드록시이소옥사졸일-C1-6알킬이며; D는 0 또는 S이며; R1는 아릴 또는 헤테로아릴기이거나 할로겐, C1-6알킬, C1-6알콕시, 히드록시, C1-6알킬티오, C1-6알킬술포닐, C1-6알킬아미노 또는 디-(C1-6알킬)아미노, 시아노, 니트로, 트리플루오로메틸 또는 트리플루오로메틸티오로부터 선택된 한개 이상의 치환기로 치환된 아릴 또는 헤테로아릴기이며; 만약 A는 메틸렌, B는 -CH(NH2)-COOH기, E는 0, D는 0 그리고 R1는 페닐 또는 할로겐 또는 메톡시로 치환된 페닐이라면, 화합물은 분명히 거울상이성질체의 순수형일 것이다.
  2. 제1항에 있어서, A는 결합 또는 C1-C3알킬렌인 것을 특징으로 하는 화합물.
  3. 제1항에 있어서, B는 -CH(NR′R″)-COOH 또는 일반식 Ⅱ (상기 식에서 R2, R3및 R4는 수소 또는 저릅알킬이거나 R4및 R2는 연결되어 임의적으로 히드록시로 치환된 C1-C3알킬렌기를 형성함)의 기인 것을 특징으로 하는 화합물.
  4. 제3항에 있어서, B는 -CH(NH2)-COOH 또는 일반식 Ⅱ (상기 식에서 각각의 R2, R3및 R4는 수소임)의 기인 것을 특징으로 하는 화합물.
  5. 제1항에 있어서, E는 0, C00, -0-(CH2)n-COO(n=1,2 또는 3) 또는 테트라졸일이고, D는 산소인 것을 특징으로 하는 화합물.
  6. 제1항에 있어서, R1은 아릴 또는 티에닐, 푸릴, 피롤일, 옥사졸일, 이소옥사졸일, 티아졸일, 이소티아졸일, 피라졸일, 이미다졸일, 트리아졸일, 옥사디아졸일, 티아디아졸일 및 테트라졸일과 같은 N, 0 및 S로부터 선택된 1~4 헤테로원자를 포함하는 5-원 방향족 헤테로아릴기, 벤조티에닐, 벤조푸라닐, 인돌릴, 페닐, 바이페닐, 피리딜, 피리미디닐, 피리다지닐, 피라지닐, 나프틸, 퀴놀일, 퀴나졸리닐, 퀴녹살리닐 및 신놀리닐로 구성된 군으로부터 선택된 헤테로아릴기이고, 그러한 아릴 또는 헤테로아릴기는 할로겐, C1-6알킬, C1-6알콕시, 히드록시, C1-6알킬티오, C1-6알킬술포닐, C1-6알킬아미노 또는 디-(C1-6알킬)아미노, 시아노, 니트로, 트리플루오로메틸 또는 트리플루오로메틸티오로부터 선택된 한개 이상의 치환기로 치환되는 것을 특징으로 하는 화합물.
  7. 제6항에 있어서, R1은 티에닐, 옥사졸일, 이소옥사졸일, 티아졸일, 이소티아졸일, 피라졸일, 이미다졸일, 옥사디아졸일, 티아디아졸일, 테트라졸일, 티아졸일, 피리닐, 페닐, 바이페닐 또는 나프틸이거나 할로겐 또는 메틸로 치환된 테이닐, 옥사디아졸일 또는 페닐인 것을 특징으로 하는 화합물.
  8. 제7항에 있어서, R1은 2-티에닐, 3-티에닐, 페닐, 2-피리딜 또는 4-피리딜이거나 할로겐 또는 메틸로 치환된 2-티에닐 또는 페닐인 것을 특징으로 하는 화합물.
  9. 제1항에 있어서, A는 결합 또는 C1-C3알킬렌이고, B는 -CH(NH2)-COOH 또는 일반식 Ⅱ(상기 식에서 각각의 R3, R4및 R5는 수소임)의 기이고, E 및 D는 둘다 산소이고, R1은 2-피리딜, 4-피리딜, 티에닐, 페닐, 치환된 티에닐 또는 치환된 페닐인 것을 특징으로 하는 화합물.
  10. 제1항 내지 제9항 중 어느 한 항에 따른 화합물과 함께 약학적으로 허용가능한 담체 또는 희석제로 이루어진 것을 특징으로 하는 약제조성물.
  11. 뇌허혈, Huntington 질병, 간질병, Parkinson 질병, Alzheimer 질병, 정신분열증, 동통, 우울증 또는 불안의 치료를 위한 약제조성물을 제조하기 위한 제1항 내지 제9항 중 어느 한 항에 따른 화합물의 사용.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960702307A 1993-11-03 1994-11-02 5-아릴이소옥사졸-4-일-치환된 2-아미노카르복실산 화합물(5-arylisoxa-zol-4-yl-substituted 2-amino carboxylic acid compounds) KR960705797A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK931243A DK124393D0 (da) 1993-11-03 1993-11-03 Compounds
DK1243/93 1993-11-03
PCT/DK1994/000411 WO1995012587A1 (en) 1993-11-03 1994-11-02 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds

Publications (1)

Publication Number Publication Date
KR960705797A true KR960705797A (ko) 1996-11-08

Family

ID=8102626

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702307A KR960705797A (ko) 1993-11-03 1994-11-02 5-아릴이소옥사졸-4-일-치환된 2-아미노카르복실산 화합물(5-arylisoxa-zol-4-yl-substituted 2-amino carboxylic acid compounds)

Country Status (17)

Country Link
EP (2) EP0994107A1 (ko)
JP (1) JPH09504531A (ko)
KR (1) KR960705797A (ko)
CN (1) CN1056837C (ko)
AU (1) AU680062B2 (ko)
CA (1) CA2175685A1 (ko)
CZ (1) CZ127296A3 (ko)
DK (1) DK124393D0 (ko)
FI (1) FI961872A (ko)
HU (1) HUT74692A (ko)
NO (1) NO306159B1 (ko)
NZ (1) NZ275088A (ko)
PL (1) PL314182A1 (ko)
RU (1) RU2138488C1 (ko)
SK (1) SK56496A3 (ko)
WO (1) WO1995012587A1 (ko)
ZA (1) ZA948631B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1996025405A1 (en) * 1995-02-13 1996-08-22 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
UA52698C2 (uk) * 1996-10-04 2003-01-15 Х. Луннбек А/С Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
IT1318636B1 (it) * 2000-07-21 2003-08-27 Roberto Pellicciari Derivati dell'acido 2- o 3- tenoico ad attivita' antagonista deirecettori del glutammato.
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
DE602004029146D1 (de) 2003-04-09 2010-10-28 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkylphosphonsäure und deren verwendung als n-methyl-d-aspartat- (nmda-) rezeptorantagonisten
GT200400213A (es) 2003-10-22 2007-09-05 Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
WO2008103185A2 (en) * 2006-06-08 2008-08-28 Eli Lilly And Company Substituted carboxamides as group i metabotropic receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69102816T2 (de) * 1990-05-11 1995-03-16 Sankyo Co Piperdinyloxy- und Chinindidinyloxy- isoxazol- Derivate, ihre Herstellung und ihre therapeutische Verwendung.
JPH08502508A (ja) * 1992-10-23 1996-03-19 メルク シヤープ エンド ドーム リミテツド ドーパミンレセプターサブタイプリガンド

Also Published As

Publication number Publication date
HU9601167D0 (en) 1996-07-29
WO1995012587A1 (en) 1995-05-11
FI961872A0 (fi) 1996-05-02
NO961783L (no) 1996-06-25
EP0994107A1 (en) 2000-04-19
HUT74692A (en) 1997-01-28
AU680062B2 (en) 1997-07-17
CZ127296A3 (en) 1996-09-11
DK124393D0 (da) 1993-11-03
FI961872A (fi) 1996-05-03
NO306159B1 (no) 1999-09-27
SK56496A3 (en) 1996-12-04
CN1136810A (zh) 1996-11-27
NZ275088A (en) 1997-08-22
NO961783D0 (no) 1996-05-02
CN1056837C (zh) 2000-09-27
EP0726896A1 (en) 1996-08-21
CA2175685A1 (en) 1995-05-11
JPH09504531A (ja) 1997-05-06
PL314182A1 (en) 1996-09-02
ZA948631B (en) 1995-07-10
RU2138488C1 (ru) 1999-09-27
AU8057994A (en) 1995-05-23

Similar Documents

Publication Publication Date Title
KR920701131A (ko) N-페닐알킬 치환된 α-아미노 카복사미드 유도체 및 이의 제조방법
TWI327137B (ko)
CN102137592B (zh) 用于治疗癌症的化合物
KR101245062B1 (ko) 칼슘이온-방출-활성화-칼슘이온 채널을 조절하는 방법
EP2481725B1 (en) Substituted amide compound
JP5674828B2 (ja) Ｐｄｅ１０インヒビターならびに関連する組成物および方法
KR20070107022A (ko) 염증 및 면역 관련 용도를 위한 화합물
JP5731479B2 (ja) Ｈｓｐ９０阻害剤としてのレゾルシノール誘導体
RU2013141413A (ru) Производные изоксазолина для борьбы с беспозвоночными паразитами
CA2450922A1 (en) Piperidines for use as orexin receptor antagonists
RU2011114982A (ru) Модуляторы нмда-рецептора и их применения
DE69813896T2 (de) Alpha-aminoamidderivate die als analgetische mittel nützlich sind
CY1109273T1 (el) Ενωσεις πιπεριδινης και φαρμακευτικες συνθεσεις που τις περιεχουν
KR970061888A (ko) 신규한 치환 옥사졸리디논
CO5271680A1 (es) Compuestos
KR940018360A (ko) 아릴설폰아미도-치환된 하이드록삼산
JP2006506455A5 (ko)
JP2008526840A5 (ko)
RU2007129779A (ru) Новые соединения пиридина
KR960705797A (ko) 5-아릴이소옥사졸-4-일-치환된 2-아미노카르복실산 화합물(5-arylisoxa-zol-4-yl-substituted 2-amino carboxylic acid compounds)
HRP20100229T1 (hr) Terapeutski agensi korisni za liječenje boli
KR880009936A (ko) 피리딘-2,4-및-2,5-디카복실산 아미드, 그의 제조방법 및 용도
KR920701179A (ko) 살진균성 옥사졸리디논
RU2017134379A (ru) Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
JP2009514899A5 (ko)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application